Maria Dimitrova
Datos Biográficos
| ID | 9993285 |
|---|---|
| NOMBRE | Maria Dimitrova |
| NOMBRES | Maria |
| APELLIDO | Dimitrova |
| FIRMA | DIMITROVA M |
| AFILIACIONES | Medical University of Sofia |
| ORCID | 0000-0002-4868-7775 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 6 |
| TOTAL DE CITAS | 0 |
| OBRAS COMO AUTOR | 6 |
| OBRAS COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2020 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2023 |
| ÍNDICE H | 0 |
Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
Introduction: Meaningful patient involvement in health technology assessment (HTA) is essential in ensuring that the interests of the affected patient population, their families, and the general public are accurately reflected in coverage and reimbursement decisions. Central and Eastern European (CEE) countries are generally at less advanced stages of implementing HTA, which is particularly true for patient involvement activities. As part of the …
Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria
Introduction Breast cancer is the most common type of cancer affecting women in Europe. Advanced breast cancer (ABC) poses a significant therapeutic challenge, and therefore, timely access to treatment is crucial. The aim of the present study was to evaluate the treatment patterns and patients' access to new therapies for ABC in Bulgaria. Methods We conducted a retrospective study in the period 2008–2021. Based on the European Medicines Agency (E…
Budget cap and pay-back model to control spending on medicines
Central and Eastern European countries (CEEC) have among the highest rates of increase in healthcare expenditure. External reference pricing, generics and biologics price capping, regressive scale for price setting, health technology assessment (HTA), and positive drug lists for reimbursed medicines are among the variety of implemented cost-containment measures aimed at reducing and controlling the rising cost for pharmaceuticals. The aim of our …
Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries
Patients' perspectives are important to identify preferences, estimate values and appreciate unmet medical needs in the process of research and development and subsequent assessment of new health technologies. Patient and public involvement in health technology assessment (HTA) is essential in understanding and assessing wider implications of coverage and reimbursement decisions for patients, their relatives, caregivers, and the general populatio…
Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
The aim of this paper is to identify the barriers that are specifically relevant to the use of Artificial Intelligence (AI)-based evidence in Central and Eastern European (CEE) Health Technology Assessment (HTA) systems. The study relied on two main parallel sources to identify barriers to use AI methodologies in HTA in CEE, including a scoping literature review and iterative focus group meetings with HTx team members. Most of the other selected …
New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
Background: Acromegaly and its comorbidities affect the patients’ quality of life, each healthcare system and the society. This study aimed to evaluate clinical characteristics and treatment patterns and the economic burden of acromegaly. Materials and methods: All patients with acromegaly treated with expensive medicines and regularly followed up at the main expert clinical center for acromegaly in the country were included in this nationwide, r…
Sin obras prominentes en esta página.
Budget cap and pay-back model to control spending on medicines
Central and Eastern European countries (CEEC) have among the highest rates of increase in healthcare expenditure. External reference pricing, generics and biologics price capping, regressive scale for price setting, health technology assessment (HTA), and positive drug lists for reimbursed medicines are among the variety of implemented cost-containment measures aimed at reducing and controlling the rising cost for pharmaceuticals. The aim of our …
Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries
Patients' perspectives are important to identify preferences, estimate values and appreciate unmet medical needs in the process of research and development and subsequent assessment of new health technologies. Patient and public involvement in health technology assessment (HTA) is essential in understanding and assessing wider implications of coverage and reimbursement decisions for patients, their relatives, caregivers, and the general populatio…
Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
The aim of this paper is to identify the barriers that are specifically relevant to the use of Artificial Intelligence (AI)-based evidence in Central and Eastern European (CEE) Health Technology Assessment (HTA) systems. The study relied on two main parallel sources to identify barriers to use AI methodologies in HTA in CEE, including a scoping literature review and iterative focus group meetings with HTx team members. Most of the other selected …
Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
Introduction: Meaningful patient involvement in health technology assessment (HTA) is essential in ensuring that the interests of the affected patient population, their families, and the general public are accurately reflected in coverage and reimbursement decisions. Central and Eastern European (CEE) countries are generally at less advanced stages of implementing HTA, which is particularly true for patient involvement activities. As part of the …
Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria
Introduction Breast cancer is the most common type of cancer affecting women in Europe. Advanced breast cancer (ABC) poses a significant therapeutic challenge, and therefore, timely access to treatment is crucial. The aim of the present study was to evaluate the treatment patterns and patients' access to new therapies for ABC in Bulgaria. Methods We conducted a retrospective study in the period 2008–2021. Based on the European Medicines Agency (E…
New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
Background: Acromegaly and its comorbidities affect the patients’ quality of life, each healthcare system and the society. This study aimed to evaluate clinical characteristics and treatment patterns and the economic burden of acromegaly. Materials and methods: All patients with acromegaly treated with expensive medicines and regularly followed up at the main expert clinical center for acromegaly in the country were included in this nationwide, r…
Health Systems, Economic Evaluations, Quality of Life (5 obras) · Medicine (5 obras) · Health care (4 obras) · Health technology (3 obras) · Political science (3 obras) · Reimbursement (3 obras) · Biomedical Ethics and Regulation (2 obras) · Business (2 obras) · Economic growth (2 obras) · Environmental health (2 obras)